Abstract
Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.
Keywords: Ratiometric sensing, Hyaluronidase, HA-FRET, Bladder cancer.
Current Pharmaceutical Biotechnology
Title:FRET Based Ratio-Metric Sensing of Hyaluronidase in Synthetic Urine as a Biomarker for Bladder and Prostate Cancer
Volume: 14 Issue: 4
Author(s): Rahul Chib, Sangram Raut, Rafal Fudala, Aaron Chang, Mark Mummert, Ryan Rich, Zygmunt Gryczynski and Ignacy Gryczynski
Affiliation:
Keywords: Ratiometric sensing, Hyaluronidase, HA-FRET, Bladder cancer.
Abstract: Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.
Export Options
About this article
Cite this article as:
Chib Rahul, Raut Sangram, Fudala Rafal, Chang Aaron, Mummert Mark, Rich Ryan, Gryczynski Zygmunt and Gryczynski Ignacy, FRET Based Ratio-Metric Sensing of Hyaluronidase in Synthetic Urine as a Biomarker for Bladder and Prostate Cancer, Current Pharmaceutical Biotechnology 2013; 14 (4) . https://dx.doi.org/10.2174/13892010113149990222
DOI https://dx.doi.org/10.2174/13892010113149990222 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Uterine Function: From Normal to Polycystic Ovarian Syndrome Alterations
Current Medicinal Chemistry The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Annexins as Neuroprotective Agents in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Immunological Aspects of the Prostate Gland and Related Diseases
Current Immunology Reviews (Discontinued) Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
Current Cancer Drug Targets MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers In Vivo Cellular Imaging for Translational Medical Research
Current Medical Imaging Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters Therapeutic Boosting of the Immune Response: Turning to CD14 for Help
Current Pharmaceutical Biotechnology Immunonutrition in Surgical Patients
Current Drug Targets Relevance of Pharmacokinetics and Bioavailability of Intranasal Corticosteroids in Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets Genistein Inhibits Cell Growth and Induces Apoptosis Through Up-regulation of miR-34a in Pancreatic Cancer Cells
Current Drug Targets